A retrospective study to identify risk factors for somnolence and dizziness in patients treated with pregabalin

Hiroshi Kato¹,²*, Masayuki Miyazaki¹,², Mio Takeuchi², Hiroaki Tsukuura³, Mihoko Sugishita³, Yukihiro Noda¹,² and Kiyofumi Yamada¹

Abstract

Background: Pregabalin is a therapeutic drug for neuropathic pain that is associated with somnolence and dizziness. These adverse events are often experienced shortly after initiating pregabalin, and may lead to treatment discontinuation. The purpose of this study was to explore factors that influence the incidence of somnolence and dizziness induced by pregabalin, and to identify patients at higher risk of adverse events.

Methods: A retrospective analysis was conducted of patient characteristics (age, gender, renal function, initial daily dose of pregabalin, co-administration of strong opioids and hypnotics) and the incidence of somnolence and dizziness during the first week of pregabalin treatment. An electronic chart was used to collect data from 204 inpatients prescribed pregabalin at Nagoya University Hospital from June 2011 to November 2012.

Results: Among 36 patients who regularly received strong opioids, 18 (50.0 %) reported somnolence or dizziness during the first week of pregabalin treatment. The remaining 168 patients did not regularly receive strong opioids, and 25 (14.9 %) had an adverse event. In multivariate analysis, age (≧65 years, adjusted odds ratio: 2.507, 95 % CI: 1.164-5.397, p = 0.019) and regular co-administration of strong opioids (adjusted odds ratio: 5.507, 95 % CI: 2.460-12.328, p < 0.001) correlated with somnolence or dizziness.

Conclusions: These data suggest that age (≧65 years) and co-administration of strong opioids are risk factors for somnolence or dizziness during pregabalin treatment for neuropathic pain. More careful dose titration is recommended for elderly patients and those receiving concomitant strong opioids.

Keywords: Pregabalin, Somnolence, Dizziness, Neuropathic pain, Cancer pain, Opioid, Risk factor

Background

The World Health Organization (WHO) analgesic ladder has been demonstrated to be effective for the treatment of cancer pain [1]. Patients with moderate-to-severe pain are candidates for starting strong opioid agents. However, because neuropathic cancer pain is resistant to opioids, certain adjuvant drugs are administered, including pregabalin, gabapentin, and duloxetine, and these have been shown to be effective [2–4].

Pregabalin is indicated for the management of neuropathic pain associated with diabetic peripheral neuropathy, postherpetic neuralgia, and spinal cord injury, and for the treatment of fibromyalgia. Pregabalin was first developed as an antiepileptic drug, and its efficacy for various types of neuropathic pain was demonstrated at a later time [5]. The efficacy of pregabalin for neuropathic pain has been attributed to modulation of glutamate release from hyperexcited neurons via binding to the alfa-2-delta (α2-δ) subunit of voltage-gated calcium channels, which modulates calcium influx to presynaptic terminals [6, 7]. Pharmacokinetic studies of pregabalin reveal that it is more than 90 % renally excreted as unchanged drug [8]. Accordingly, its clearance is reduced in patients with renal impairment [9].

* Correspondence: hk-hiroshi@med.nagoya-u.ac.jp
¹ Department of Neuropsychopharmacology and Hospital Pharmacy, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya, Aichi 466-8560, Japan
² Division of Clinical Sciences and Neuropsychopharmacology, Meijo University Faculty of Pharmacy, Nagoya, Japan

© 2015 Kato et al. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
The most common adverse events related to pregabalin treatment are somnolence and dizziness, which increase in a dose-dependent manner and represent the most frequent reasons for discontinuation of treatment [10–12]. Previous studies indicate that somnolence and dizziness associated with pregabalin therapy are transient, and most commonly reported in the first week of treatment, with a lower incidence thereafter [11–14]. Thus, careful dose titration to the highest tolerable dose is the most appropriate approach.

Neuropathic cancer pain is a frequent complication of cancer or its treatment, with approximately one-third of cancer pain cases involving a neuropathic component [15, 16]. Previous studies have demonstrated that adjuvant drugs, such as pregabalin, are efficacious for the treatment of neuropathic pain, although the majority of data have been obtained from non-cancer studies [17–20]. Recently, it has been reported that the neuropathic component of cancer pain responds more effectively to pregabalin than to strong opioids such as transdermal fentanyl [21]. Adjuvant drugs for the treatment of neuropathic cancer pain are included in recent clinical recommendations, usually as an add-on to opioids [22]. Therefore, cancer patients with pain who receive pregabalin treatment are often treated with opioids, which have inhibitory effects on the central nervous system. It is assumed that the combination of pregabalin with opioids may potentiate somnolence and dizziness.

The purpose of this study was to explore risk factors that influence the incidence of somnolence and dizziness induced by pregabalin, and to identify patients at higher risk of adverse events who require more careful administration of pregabalin.

**Methods**

**Study procedures**

This retrospective study was approved by the ethical committee of Nagoya University Hospital. Inpatients who were prescribed pregabalin (Lyrica® capsule) at Nagoya University Hospital from June 2011 to November 2012 were included. Exclusion criteria included patients who had initiated pregabalin treatment as an outpatient or in other hospitals, and presented somnolence, dizziness, or consciousness disorder caused by medication or electrolyte imbalance such as hypercalcemia at the time starting pregabalin treatment.

Patients’ baseline characteristics, including age, gender, renal function, neuropathic pain origin, initial dose of pregabalin (mg per day), co-administration of strong opioids (morphine, oxycodone, and fentanyl, except when used solely for rescue), co-administration of hypnotics, and the incidence of somnolence and dizziness during the first week of pregabalin treatment were retrospectively examined using an electronic chart. Creatinine clearance (CLcr), as a measure of renal function, was evaluated using the Cockcroft-Gault equation as follows:

\[
\text{CLcr (mL/min)} = \left(\frac{140 \times \text{age}}{\text{weight (kg)}} \right) \times \left(\frac{72}{\text{serum creatinine (mg/dL)}} \right) \times 0.85 \text{ (if female)}
\]

**Statistical analysis**

To identify factors associated with the incidence of adverse events (somnolence or dizziness), univariate analysis was performed using age, gender, regular co-administration of strong opioids, renal function, initial dose of pregabalin, pregabalin dose group, and regular co-administration of hypnotics as independent variables. Factors with a p-value <0.05 in univariate analysis were evaluated as potential covariates in multivariate analysis using logistic regression modeling. All statistical analyses were performed using SPSS version 22 (SPSS Inc., USA). P-values <0.05 were considered to denote statistically significant differences.

**Results**

**Patient characteristics**

The study included 204 patients [male: 123 (60.3 %), female: 81 (39.7 %)] with a median age of 61 years (range: 18–92). Thirty-six patients (17.6 %) were regularly administered strong opioids (fentanyl: n = 17, oxycodone: n = 16, morphine: n = 3). The median dose of regular opioid (converted to oral morphine) was 60 mg/day (range: 15–300 mg/day). Initial dosages of pregabalin were 25 (n = 4), 50 (n = 3), 75 (n = 73), and 150 mg/day (n = 124) (Table 1).

**Relationship between renal function and adverse events**

Initial doses of pregabalin according to renal function (CLcr) are depicted in Table 2. In patients with normal renal function (CLcr ≥ 60 mL/min), a total daily dose of 150 mg pregabalin is recommended initially. In patients with impaired renal function, the total daily dose of pregabalin was reduced according to the degree of renal function (60 > CLcr ≥ 30 mL/min: 75 mg/day, 30 > CLcr ≥ 15 mL/min: 25–50 mg/day, 15 mL/min > CLcr: 25 mg/day).

Based on the initial dosing recommendations for differing degrees of renal function in the prescribing information of Lyrica capsules [10], patients were divided into three groups: “high dose group”, “regular dose group”, and “low dose group”. The incidence of somnolence or dizziness in each group is presented in Table 3. Seven (43.8 %) of 16 patients in the high dose group, 28 (21.1 %) of 133 patients in the regular dose group, and 8 (14.5 %) of 55 patients in low dose group reported somnolence or dizziness.
Univariate analysis

Table 4 displays the relationship between each factor (age, gender, regular co-administration of strong opioids, renal function (CLcr), initial dose of pregabalin, pregabalin dose group, and regular co-administration of hypnotics) and incidence of adverse events (somnolence or dizziness) determined by univariate analysis. Among patients who regularly used strong opioids with pregabalin, 18 (50.0 %) of 36 exhibited somnolence or dizziness during the first week of pregabalin therapy. In contrast, adverse events were reported by only 25 (14.9 %) of the 168 patients who did not regularly receive strong opioids. Age (≧65 years), regular co-administration of strong opioids, renal function (CLcr < 60 mL/min), and high pregabalin doses were related to adverse events. Among these factors, regular co-administration of strong opioids had the highest odds ratio (odds ratio: 5.720, 95 % CI: 2.624-12.470, p < 0.001).

Multivariate analysis

The results of multivariate analysis are presented in Table 5. Independent variables included: age, regular co-administration of strong opioids, renal function (CLcr), and pregabalin dose group. The dependent variable was incidence of adverse events (somnolence or dizziness). Age (≧65 years, adjusted odds ratio: 2.507, 95 % CI: 1.164-5.397, p = 0.019) and regular co-administration of strong opioids (adjusted odds ratio: 5.507, 95 % CI: 2.647-11.537, p < 0.001) were significant factors.

Table 1 Patient characteristics (n = 204)

| Factor                   | Median, year | Range, year | Male, n(%) | Female, n(%) | Median CLcr<sub>a</sub>, mL/min |
|--------------------------|--------------|-------------|------------|--------------|-------------------------------|
| Age                      | 61           | 18-92       | 123 (60.3) | 81 (39.7)    | 88.7                          |

<sup>a</sup>CLcr: creatinine clearance using the Cockcroft-Gault equation

<sup>b</sup>NP: neuropathic pain

<sup>c</sup>Converted to oral morphine

Table 2 Distribution of initial daily doses of pregabalin according to renal function

| Renal function | Pregabalin dose (per day) | Initial dose of pregabalin (per day) | (+) | (-) |
|----------------|---------------------------|--------------------------------------|-----|-----|
|                | 25 mg (n = 4)             | 50 mg (n = 3)                        | 75 mg (n = 73) | 150 mg (n = 124) |
| CLcr<sub>a</sub> ≥ 60 | 3                        | 2                                     | 49 | 112 |
| 60 > CLcr ≥ 30 | 0                        | 1                                     | 20 | 11  |
| 30 > CLcr ≥ 15 | 1                        | 0                                     | 4  | 1   |
| 15 > CLcr       | 0                        | 0                                     | 0  | 0   |

<sup>a</sup>CLcr: creatinine clearance (mL/min) using the Cockcroft-Gault equation

Table 3 Adverse events according to pregabalin dose group

| Pregabalin dose group | Adverse event*, n | Incidence of adverse event, % |
|-----------------------|-------------------|-------------------------------|
| High                  | 7                 | 9                             | 43.8 |
| Regular               | 28                | 105                           | 21.1 |
| Low                   | 8                 | 47                            | 14.5 |

<sup>a</sup>Adverse event: somnolence or dizziness

Table 4 Univariate analysis

| Factor                   | Adverse event<sup>a</sup>, n | Odds ratio | 95 % CI      | P-value |
|--------------------------|-----------------------------|------------|--------------|---------|
| Age                      | ≥65                         | 26         | 2.948       | 1.474-5.892 | 0.002 |
|                        | <65                         | 17         | 1.106       | 0.584-2.148 | 0.106 |
| Gender                  | male                        | 31         | 1.937       | 0.928-4.044 | 0.078 |
|                        | female                      | 12         | 1.129       | 0.515-2.542 | 0.735 |
| Regular                | strong opioid              | yes        | 18         | 1.645 | 0.799-3.387 | 0.177 |
|                        | no                          | 30         | 1.146       | 0.575-2.291 | 0.711 |
| C<sub>L</sub>cr         | <60 mL/min                  | 13         | 2.357       | 1.083-5.133 | 0.031 |
|                        | ≥60 mL/min                  | 30         | 1.465       | 0.806-2.691 | 0.199 |
| Initial dose of pregabalin | <150 mg/day               | 30         | 1.645       | 0.799-3.387 | 0.177 |
|                        | ≥150 mg/day                 | 13         | 1.146       | 0.575-2.291 | 0.711 |
| Pregabalin dose group   | high                        | 7          | 3.284       | 1.146-9.407 | 0.027 |
|                        | regular/low                 | 36         | 1.146       | 0.575-2.291 | 0.711 |
| Hypnotics              | yes                         | 8          | 1.611       | 0.655-3.962 | 0.299 |
|                        | no                          | 35         | 1.146       | 0.575-2.291 | 0.711 |

<sup>a</sup>Adverse event: somnolence or dizziness
2.460-12.328, \( p < 0.001 \) were significantly associated with the incidence of somnolence or dizziness.

### Discussion

Data from this study suggest that age and co-administration of regular strong opioids are risk factors for somnolence or dizziness in patients treated with pregabalin. Elderly patients often present with impairments in drug metabolism and excretion. Pregabalin undergoes renal excretion as an unchanged drug without hepatic metabolism [8, 23]. However, in the present multivariate analysis, renal impairment was not associated with the occurrence of somnolence and dizziness. In an analysis of patient-level data from 31 clinical trials of pregabalin, the risk of somnolence and dizziness was higher in elderly patients compared with that of other adverse events (for example, weight gain and dry mouth) [11]. This suggests that elderly patients on pregabalin therapy may have a higher risk of central nervous system adverse events such as somnolence and dizziness, but these events may not be due to renal impairment.

It has been reported that the AUC (area under the blood concentration curve) of gabapentin, a similar drug to pregabalin, is elevated when gabapentin is co-administered with morphine [24]. This is explained by the increased absorption of gabapentin because of morphine-induced gastrointestinal hypomotility. The pharmacokinetic properties of pregabalin are different from those of gabapentin. Pregabalin has greater than 90 % bioavailability, regardless of dosage, while the bioavailability of gabapentin decreases as the dose increases. Therefore, the extent of gastrointestinal absorption of pregabalin, which has high bioavailability, may not be altered by concomitant opioid administration. Pharmacodynamic, but not pharmacokinetic interaction could be suggested in co-administration of pregabalin and opioid. Pregabalin is structurally related to gamma-aminobutyric acid (GABA), but it does not bind to GABA\(_A\), GABA\(_B\), or benzodiazepine receptors [6]. Gabapentin maintains and potentiates GABAergic systems, and it suppresses neuronal activity by increasing GABA levels in the brain [25, 26]. Thus, it is possible that the modulating effects of pregabalin on GABAergic systems influence the sedative effects of opioids in an additive manner, exacerbating somnolence and dizziness. However, co-administration of hypnotics was not associated with the incidence of somnolence and dizziness significantly in our study.

In a previous report, the impact of disease conditions on the incidence of pregabalin-associated adverse events was analyzed [11]. The incidence of somnolence and dizziness in cancer patients with neuropathic pain who received pregabalin treatment was not different from that observed for other diseases such as diabetic peripheral neuropathy and postherpetic neuralgia. Although no clear relationship was observed between cancer and the incidence of somnolence and dizziness in that report, administration of pregabalin to patients on regular strong opioids increased the incidence of these adverse events according to our data.

Previously, it has been suggested that the incidence of somnolence and dizziness in patients treated with pregabalin increases in a dose-dependent manner [11, 12]. However, in the present study, the initial dose of pregabalin did not have a significant impact on adverse event rates. Differences between studies include longer observation periods of several weeks, and more variable maintenance doses of pregabalin (maximum: 600 mg/day). Thus, it is likely that the initial dose of pregabalin has minimal impact on the incidence of somnolence and dizziness.

Furthermore, high pregabalin doses were not associated with a higher incidence of somnolence or dizziness, using the initial dose recommendations based on renal function. Although the initial dose of pregabalin was adjusted according to renal function, some patients received high or low doses of pregabalin. Under such conditions, dose of pregabalin did not have a significant impact on adverse events. This aspect may need to be studied for a longer observation period in a larger sample size using high doses. In the present study, the observation period was restricted to one week and the sample size was small (high dose group; \( n = 16 \)).

The present study has limitations, including the retrospective, single-center design. Further prospective studies with a larger sample size are needed. Also, effect of hypnotics prescribed as needed is not taken into account in this study because of the limited data.

### Conclusions

In conclusion, these findings suggest that age (\( \geq 65 \) years) and co-administration of strong opioids are risk factors for somnolence or dizziness in patients on pregabalin treatment. Thus, more careful dose titration of pregabalin for neuropathic pain therapy is recommended in elderly patients, and those who receive strong opioids concomitantly.
Competing interests
The authors have declared that there are no competing interests.

Authors’ contributions
HK, MW: study design, data analysis, drafting the manuscript. MT: data analysis, HT, MS, YN, KY: study design, critical review of manuscript. All authors read and approved the final manuscript.

Acknowledgments
We thank Prof. Yuichi Ando (Department of Clinical Oncology and Chemotherapy, Nagoya University Hospital, Nagoya, Japan) for critical review of manuscript.

Author details
1Department of Neuropsychopharmacology and Hospital Pharmacy, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya, Aichi 466-8560, Japan. 2Division of Clinical Sciences and Neuropsychopharmacology, Meijo University Faculty of Pharmacy, Nagoya, Japan. 3Department of Clinical Oncology and Chemotherapy, Nagoya University Hospital, Nagoya, Japan.

Received: 28 March 2015 Accepted: 17 June 2015
Published online: 16 July 2015

References
1. World Health Organization. Cancer Pain Relief. Geneva: Office of Publications; WHO, 1986.
2. Veinckreic P, Olesjkhoz H, Kepak T, Mazanek P, Sterba J, Rysava M, et al. Efficacy of pregabalin in neuropathic pain in paediatric oncological patients. Eur J Paediatr Neuroi. 2009;13:332–6.
3. Mishra S, Bhatnagar S, Goyal GN, Okamoto W, Fujisaka Y, et al. Pilot study of duloxetine for cancer patients with neuropathic pain non-responsive to pregabalin. Anticancer Res. 2012;32:1805–9.
4. Bennett MI, Laid B, van Litsenburg C, Nimour M. Pregabalin for the management of neuropathic pain in adults with cancer: a systematic review of the literature. Pain Med. 2013;14:181–8.
5. Taylor CP, Angelotti T, Fauman E. Pharmacology and mechanism of action of pregabalin: the calcium channel alpha2-delta (alpha2-delta) subunit as a target for antiepileptic drug discovery. Epilepsy Res. 2007;73:137–50.
6. Dooley DJ, Taylor CP, Donevan S, Feltner D. Ca2+ channel alpha2delta ligands: novel modulators of neurotransmission. Trends Pharmacol Sci. 2007;28:75–82.
7. Conigran BW, Pool WF, Posvar EL, Strand JC, Alvey CW, Radulovic LL, et al. Metabolic disposition of pregabalin in healthy volunteers [abstract Pi-68]. Clin Pharmacol Ther. 2001;69:18.
8. Randinits EJ, Posvar EL, Alvey CW, Sedman AJ, Cook JA, Bockbrader HN. Pharmacokinetics of pregabalin in subjects with various degrees of renal function. J Clin Pharmacol. 2003;43:277–83.
9. Pfizer Inc. Lyrica US Prescribing Information, http://labeling.pfizer.com/ShowLabeling.aspx?id=561 (2013). Accessed 28 March 2015.
10. Freynhagen R, Serpell M, Emir B, Whalen E, Parsons B, Clair A, et al. A Comprehensive Drug Safety Evaluation of Pregabalin in Peripheral Neuropathic Pain. Pain Pract. 2015;15:47–57.
11. Gil-Naget A, Zaccara G, Baldetti F, Leon T. Add-on treatment with pregabalin for partial seizures with or without generalisation: pooled data analysis of four randomised placebo-controlled trials. Seizure. 2009;18:184–92.
12. Toelle TR, Vanara R, Nimour M, Emir B, Brasser M. Pregabalin in Neuropathic Pain Related to DPN, Cancer and Back Pain: Analysis of a 6-Week Observational Study. Open Pain J. 2012;5:1–11.
13. Saif MW, Syrigos K, Kaley K, Isuf I. Role of pregabalin in treatment of oxaliplatin-induced sensory neuropathy. Anticancer Res. 2010;30:2927–33.
14. de Paredes ML, del Moral González F, Martinez del Prado P, Martí Ciriúnál JL, Eneche Françoís S, Cobo Dols M, et al. First evidence of oncologic neuropathic pain prevalence after screening 8615 cancer patients. Results of the On study. Ann Oncol. 2011;22:2924–30.
15. Irving GA. Contemporary assessment and management of neuropathic pain. Neurology. 2005;64 Suppl 3:521–7.
16. Rosenstock J, Tuchman M, LaMoreaux L, Sharma U. Pregabalin for the treatment of painful diabetic peripheral neuropathy: a double-blind, placebo-controlled trial. Pain. 2004;110:628–38.
17. Dworkin RH, Corbin AE, Young Jr. JP, Sharma U, LaMoreaux L, Bockbrader H, et al. Pregabalin for the treatment of postherpetic neuralgia: a randomized, placebo-controlled trial. Neurology. 2006;67:1792–800.
18. Arnold LM, Russell II, Diri EW, Duan WR, Young Jr. JP, Sharma U, et al. A 14-week, randomized, double-blind, placebo-controlled monotherapy trial of pregabalin in patients with fibromyalgia. J Pain. 2008;9:792–805.
19. Baptès E, Vadalousca A, Stavropolou E, Argye E, Mekemeni A, Safaka I. Pregabalin vs. opioids for the treatment of neuropathic cancer pain: a prospective, head-to-head, randomized, open-label study. Pain Pract. 2014;14:32–42.
20. Ripamonti C, Santini D, Maranzano E, Bent M, Rola F, Group EGW. Management of cancer pain: ESMO Clinical Practice Guidelines. Ann Oncol. 2012;23 Suppl 7:vii139–54.
21. Brodie MJ. Pregabalin as adjunctive therapy for partial seizures. Epilepsia. 2004;45 Suppl 6:19–27.
22. Eckhardt K, Ammon S, Hofmann U, Riebe A, Gugeler N, Mikus G. Gabapentin enhances the analgesic effect of morphine in healthy volunteers. Anesth Analg. 2000;91:185–91.
23. Petroff OA, Hyder F, Rothman DL, Matson RH. Effects of gabapentin on brain GABA, homocarnosine, and pyrrolidinone in epidemi patients. Epilepsia. 2000;41:1657–60.
24. Cai K, Nangang RP, Lamprou I, Schinstine C, Elliott M, Hariharan H, et al. The impact of gabapentin administration on brain GABA and glutamate concentrations: a 7T 1H-MRS study. Neuropsychopharmacology.